Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
Patient Capital Management's Q4 2025 review highlights strong equity performance with the S&P 500 gaining 17.9% for the year, marking the seventh-best three-year return since 1929. Despite a sharp April drawdown and a 43-day government shutdown disrupting economic data, markets reached new highs by December. The Federal Reserve cut rates twice in the quarter, bringing the federal funds rate to 3.50-3.75%, with markets pricing two additional cuts for 2026. Technology and telecommunications led sector performance with gains of 24.0% and 33.6% respectively. Consumer spending remained resilient through the holidays despite deteriorating sentiment. Key risks include concerns over an AI-driven bubble, elevated equity valuations, and potential temporary nature of inflation improvements due to data disruptions. However, the firm maintains an optimistic outlook for 2026, citing solid economic growth, resilient consumer spending, and historical precedent that high skepticism levels often support continued market upside.
Despite elevated valuations and AI bubble concerns, solid economic growth, resilient consumer spending, and Fed easing create a favorable backdrop for continued equity gains in 2026.
As we enter 2026, solid economic growth and resilient consumer spending continue to underpin the outlook. While concerns around an AI-driven bubble and elevated equity valuations have increased, high levels of skepticism have historically been a constructive force for markets, often supporting continued upside. With equities rising in roughly 70% of years, the backdrop remains favorable for further gains.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 2 2026 | 2025 Q4 | - | AI, consumer, equities, Fed, rates, technology, Valuations | - | Concerns around an AI-driven bubble and elevated equity valuations have increased, though high levels of skepticism have historically been a constructive force for markets. |
| Oct 1 2025 | 2025 Q3 | - | cash flow, healthcare, Quality, technology, value | - | The letter highlights strong equity momentum driven by easing financial conditions, resilient consumers, and expectations of rate cuts. Patient Capital notes broad participation across sectors… |
| Jul 11 2025 | 2025 Q2 | NCLH, QXO, UNH | contrarian, Discipline, dislocation, valuation, volatility |
UNH IAC QXO |
The letter emphasizes deploying capital during periods of fear, volatility, and pessimism when prices diverge sharply from fundamentals. Management highlights that market drawdowns and macro… |
| Apr 7 2025 | 2025 Q1 | AMZN, C, NCLH, NVDA, QXO, RPRX, UAL | - | - | - |
| Jan 13 2025 | 2024 Q4 | COST, OMF, PLAY, RPRX, TSLA | - | - | - |
| Oct 8 2024 | 2024 Q3 | JPM, PLAY, QXO, XPO | - | - | - |
| Nov 7 2022 | 2024 Q2 | BIIB, DAL, EVRI, EXPE, IAC, KOS, NCLH, NVDA | - | - | - |
| Apr 25 2024 | 2024 Q1 | BIIB, C, EXPE, META, NVDA, PTON, SOFI | - | - | - |
| Jan 17 2024 | 2023 Q4 | EXPE, FTCH, UBS, WAL | - | - | - |
| Nov 10 2023 | 2023 Q3 | C CI, EXPE | - | - | - |
| Jul 14 2023 | 2023 Q2 | C, COST, JPM, WAL | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
| 2025 Q3 |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech |
Technology |
||
ValueThe manager continues to find attractive value opportunities despite expensive markets, purchasing undervalued companies like Centene, GlaxoSmithKline, Carrefour and PayPal trading at low multiples with strong fundamentals. |
Undervalued Low Multiples Contrarian Opportunistic | |
| 2025 Q2 |
Contrarian |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 11, 2025 | Fund Letters | Samantha McLemore | UNH | UnitedHealth Group Inc. | Health Care | Managed Health Care | Bull | New York Stock Exchange | Cycle, earnings, healthcare, Insurance, valuation | Login |
| Jul 11, 2025 | Fund Letters | Samantha McLemore | IAC | IAC Inc. | Communication Services | Interactive Media & Services | Bull | NASDAQ | buybacks, digital media, holding company, SOTP, valuation | Login |
| Jul 11, 2025 | Fund Letters | Samantha McLemore | QXO | QXO Inc. | Industrials | Trading Companies & Distributors | Bull | New York Stock Exchange | Building Products, Distribution, growth, M&A, Roll-up | Login |
| TICKER | COMMENTARY |
|---|---|
| No ticker commentary found. | |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||